Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05470348RecruitingPhase 1
Test drug BL-B01D1 for advanced breast and other solid cancers
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
Guangzhou, GuangdongAges 18–75 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT05474573Recruiting
Laser-guided removal of brain tumors using special light
This study tests a method to help surgeons find and remove brain tumors that show up on MRI with contrast dye (often high-grade gliomas and brain metastases). If you newly have one of these tumors, the trial may help improve how completely tumors can be removed while protecting important brain areas.
MoscowAges 18–79 - NCT05480644Recruiting
Blood biomarker study for brain tumor patients
This study collects blood (and looks at samples) from adults who have a confirmed brain tumor, either one that started in the brain or one that spread to the brain. The goal is to understand biomarkers—signals in the body—that may help improve diagnosis or tracking over time.
Durham, North CarolinaAges 18 years+ - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05495295RecruitingPhase 1
First test of PhOx430 for advanced solid tumors
This Phase 1 trial tests a new cancer drug, PhOx430, for people with advanced (metastatic) solid tumors that have not responded to standard treatments. It aims to find a safe dose and to see whether the drug can shrink or control cancer.
MontpellierAges 18–80 - NCT05504772Recruiting
Personalized genetic testing for children with cancer
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
AdelaideAges birth–25 years - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05528055RecruitingPhase 1
Safety study of SCR-6920 for advanced cancers
This Phase 1 trial tests whether SCR-6920 capsules are safe and tolerable in people with advanced, treatment-resistant cancers. It may help doctors learn the right way to dose the medicine and check for side effects.
Jinan, ShandongAges 18–75 - NCT05529615Recruiting
Blood DNA test guides chemotherapy after colon cancer surgery
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
Beijing, Beijing MunicipalityAges 18–75 - NCT05532696RecruitingPhase 1/Phase 2
Testing ABT-101 for advanced solid tumors and HER2-mutant lung cancer
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
TaichungAges 18 years+ - NCT05536141RecruitingPhase 1
Study of AB521 for kidney cancer and other solid tumors
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
Birmingham, AlabamaAges 18 years+ - NCT05544240RecruitingPhase 1
First-in-human immunotherapy study for advanced solid tumors
This Phase 1 trial tests SYNC-T, an immunotherapy, in people with advanced or metastatic solid cancers. It aims to find the safest dose and see whether the treatment can shrink or control tumors.
Mexico CityAges 18 years+ - NCT05549024RecruitingEarly Phase 1
PET/CT scan study for certain prostate, brain, or breast cancers
This early-phase study tests special PET/CT scans using a radioactive tracer to see cancer areas that have specific targets. It may help doctors better visualize tumors and plan next steps, using scans that you may already be familiar with (FDG) plus targeted tracers.
BeijingAges 18 years+ - NCT05556473RecruitingPhase 1
Tryptophan PET/CT scan study for different tumors
This early-phase study tests a special PET/CT scan using labeled tryptophan to help doctors see how different tumors behave. The goal is to learn whether this scan can better identify and measure cancers in the brain or elsewhere.
Detroit, MichiganAges 18 years+ - NCT05557045RecruitingPhase 1
Trial of an oral pill for MAPK-driven advanced solid tumors
This Phase 1 study tests an oral investigational medicine (JZP815) to see how safe it is, the best dose, and whether it can shrink tumors. It’s for adults with advanced or metastatic solid cancers that have a specific MAPK pathway genetic change.
Los Angeles, CaliforniaAges 18 years+ - NCT05559853Recruiting
MRI scan study to track brain tumor changes after treatment
This study tests a new MRI (brain scan) method to see how brain tumors change over time after treatment. There are also parts for healthy adults to help with developing and comparing the scan technique.
New York, New YorkAges 18 years+ - NCT05571579Recruiting
Collecting blood and tissue samples from confirmed brain tumors
This study collects biological samples from adults with a confirmed brain tumor. Samples may help researchers better understand brain tumors and improve future treatments.
Bron, RhôneAges 18 years+ - NCT05572216Recruiting
Robot-assisted kidney tumor surgery with 3D imaging guidance
This study compares a robot-assisted kidney-sparing surgery guided by 3D images. It aims to improve how precisely surgeons remove a complex kidney tumor while protecting kidney function.
GrenobleAges 18 years+ - NCT05589207Recruiting
Model to predict outcomes in kidney cancer with IVC wall invasion
This study uses information from scans and surgery findings to build a prediction model for people with kidney cancer that has grown into a major vein (the IVC). It aims to help doctors better estimate outcomes and guide care after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05593146RecruitingPhase 2
3D hip reconstruction surgery to prevent dislocation
This trial compares a modified hip implant positioning method to lower the chance of the hip “slipping out of place” (dislocation) after major hip tumor surgery and reconstruction. If you qualify, you may help test whether a small change in implant angle improves stability and function.
Ningbo, ZhejiangAges 16 years+ - NCT05595603RecruitingPhase 2
Zoledronic acid in bone cement after tumor scraping
This trial tests whether adding zoledronic acid (a bone-strengthening medicine) into bone cement at the surgical site can help prevent giant cell bone tumor from coming back after surgeons scrape it out from inside the bone. It is for people whose tumor can be treated with a specific “scrape-and-reconstruct” surgery and who have not had related medicines before.
HangzhouAges Any age - NCT05596344Recruiting
Long-term check-in for anxiety and depression in cancer patients
This study will follow people with cancer over time to learn how anxiety and depression change. It may help doctors understand what support patients need and when.
Zhengzhou, HenanAges Any age - NCT05598528Recruiting
Study why some lung cancers don’t respond to EGFR pills
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Changsha, HunanAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.